                         SEQUENCE LISTING

<110>  Regeneron Pharmaceuticals, Inc.
 
<120>  Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye Disorders

<130>  10861WO01


<150>  63/189,541
<151>  2021-05-17

<150>  63/235,398
<151>  2021-08-20

<150>  63/297,420
<151>  2022-01-07

<150>  63/306,315
<151>  2022-02-03

<160>  2

<170>  PatentIn version 3.5

<210>  1
<211>  1377
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  synthetic

<400>  1
atggtcagct actgggacac cggggtcctg ctgtgcgcgc tgctcagctg tctgcttctc       60

acaggatcta gttccggaag tgataccggt agacctttcg tagagatgta cagtgaaatc      120

cccgaaatta tacacatgac tgaaggaagg gagctcgtca ttccctgccg ggttacgtca      180

cctaacatca ctgttacttt aaaaaagttt ccacttgaca ctttgatccc tgatggaaaa      240

cgcataatct gggacagtag aaagggcttc atcatatcaa atgcaacgta caaagaaata      300

gggcttctga cctgtgaagc aacagtcaat gggcatttgt ataagacaaa ctatctcaca      360

catcgacaaa ccaatacaat catagatgtg gttctgagtc cgtctcatgg aattgaacta      420

tctgttggag aaaagcttgt cttaaattgt acagcaagaa ctgaactaaa tgtggggatt      480

gacttcaact gggaataccc ttcttcgaag catcagcata agaaacttgt aaaccgagac      540

ctaaaaaccc agtctgggag tgagatgaag aaatttttga gcaccttaac tatagatggt      600

gtaacccgga gtgaccaagg attgtacacc tgtgcagcat ccagtgggct gatgaccaag      660

aagaacagca catttgtcag ggtccatgaa aaggacaaaa ctcacacatg cccaccgtgc      720

ccagcacctg aactcctggg gggaccgtca gtcttcctct tccccccaaa acccaaggac      780

accctcatga tctcccggac ccctgaggtc acatgcgtgg tggtggacgt gagccacgaa      840

gaccctgagg tcaagttcaa ctggtacgtg gacggcgtgg aggtgcataa tgccaagaca      900

aagccgcggg aggagcagta caacagcacg taccgtgtgg tcagcgtcct caccgtcctg      960

caccaggact ggctgaatgg caaggagtac aagtgcaagg tctccaacaa agccctccca     1020

gcccccatcg agaaaaccat ctccaaagcc aaagggcagc cccgagaacc acaggtgtac     1080

accctgcccc catcccggga tgagctgacc aagaaccagg tcagcctgac ctgcctggtc     1140

aaaggcttct atcccagcga catcgccgtg gagtgggaga gcaatgggca gccggagaac     1200

aactacaaga ccacgcctcc cgtgctggac tccgacggct ccttcttcct ctacagcaag     1260

ctcaccgtgg acaagagcag gtggcagcag gggaacgtct tctcatgctc cgtgatgcat     1320

gaggctctgc acaaccacta cacgcagaag agcctctccc tgtctccggg taaatga        1377



<210>  2
<211>  458
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic

<400>  2

Met Val Ser Tyr Trp Asp Thr Gly Val Leu Leu Cys Ala Leu Leu Ser
1               5                   10                  15


Cys Leu Leu Leu Thr Gly Ser Ser Ser Gly Ser Asp Thr Gly Arg Pro
            20                  25                  30


Phe Val Glu Met Tyr Ser Glu Ile Pro Glu Ile Ile His Met Thr Glu
        35                  40                  45


Gly Arg Glu Leu Val Ile Pro Cys Arg Val Thr Ser Pro Asn Ile Thr
    50                  55                  60


Val Thr Leu Lys Lys Phe Pro Leu Asp Thr Leu Ile Pro Asp Gly Lys
65                  70                  75                  80


Arg Ile Ile Trp Asp Ser Arg Lys Gly Phe Ile Ile Ser Asn Ala Thr
                85                  90                  95


Tyr Lys Glu Ile Gly Leu Leu Thr Cys Glu Ala Thr Val Asn Gly His
            100                 105                 110


Leu Tyr Lys Thr Asn Tyr Leu Thr His Arg Gln Thr Asn Thr Ile Ile
        115                 120                 125


Asp Val Val Leu Ser Pro Ser His Gly Ile Glu Leu Ser Val Gly Glu
    130                 135                 140


Lys Leu Val Leu Asn Cys Thr Ala Arg Thr Glu Leu Asn Val Gly Ile
145                 150                 155                 160


Asp Phe Asn Trp Glu Tyr Pro Ser Ser Lys His Gln His Lys Lys Leu
                165                 170                 175


Val Asn Arg Asp Leu Lys Thr Gln Ser Gly Ser Glu Met Lys Lys Phe
            180                 185                 190


Leu Ser Thr Leu Thr Ile Asp Gly Val Thr Arg Ser Asp Gln Gly Leu
        195                 200                 205


Tyr Thr Cys Ala Ala Ser Ser Gly Leu Met Thr Lys Lys Asn Ser Thr
    210                 215                 220


Phe Val Arg Val His Glu Lys Asp Lys Thr His Thr Cys Pro Pro Cys
225                 230                 235                 240


Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
                245                 250                 255


Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
            260                 265                 270 


Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
        275                 280                 285


Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
    290                 295                 300


Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
305                 310                 315                 320


His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
                325                 330                 335


Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
            340                 345                 350


Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu
        355                 360                 365


Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
    370                 375                 380


Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
385                 390                 395                 400


Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
                405                 410                 415


Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
            420                 425                 430


Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
        435                 440                 445


Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
    450                 455
